In vitro and in vivo activities of clarithromycin against Mycobacterium avium.

There is no effective therapy to treat Mycobacterium avium complex infection in patients with acquired immune deficiency syndrome. Clarithromycin (A-56268; TE-031) is a new macrolide which is twofold more active than erythromycin against most aerobic bacteria. In addition, higher levels in serum and...

ver descrição completa

Detalhes bibliográficos

Publicado no:	Antimicrob Agents Chemother
Principais autores:	Fernandes, P B, Hardy, D J, McDaniel, D, Hanson, C W, Swanson, R N
Formato:	Artigo
Idioma:	Inglês
Publicado em:	American Society for Microbiology (ASM) 1989
Assuntos:	Research Article
Acesso em linha:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC172696/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/2530933/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.33.9.1531
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!